Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2160347 | Radiotherapy and Oncology | 2008 | 5 Pages |
Abstract
Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p = 0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Katsuyuki Karasawa, Makoto Sunamura, Atsutake Okamoto, Kenji Nemoto, Seiki Matsuno, Yasumasa Nishimura, Yuta Shibamoto,